Canadian drugmaker Valeant Pharmaceuticals International Inc. has agreed to buy Salix Pharmaceuticals Ltd. for about $10 billion in cash.
February 26, 2015 at 12:00 AM
1 minute read
Canadian drugmaker Valeant Pharmaceuticals International Inc. has agreed to buy Salix Pharmaceuticals Ltd. for about $10 billion in cash.
The companies said Sunday that their boards of directors approved the transaction, which amounts to about $158 for each of Salix’s outstanding shares—just above the Raleigh, North Carolina-based Salix’s closing price of $157.85 per share on Friday.
Presented by BigVoodoo
Celebrating achievement, excellence, and innovation in the legal profession in the UK.
Join the industry's top owners, investors, developers, brokers and financiers for the real estate healthcare event of the year!
This event shines a spotlight on how individuals and firms are changing the investment advisory industry where it matters most.
Downtown NY property and casualty defense law firm seeks a Litigation Associate with 3+ years' experience to become a part of our team! You ...
Description: Fox Rothschild has an opening in the New York office for a Counsel in our renowned Labor & Employment Department, working w...
Our client, a large, privately-owned healthcare company, has engaged us to find an Assistant General Counsel for their headquarters located ...
